Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-09-29
2011-11-08
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
08053430
ABSTRACT:
Methods are provided of treating renal cancer by administration of certain 3,3′,4,4′-tetrahydroxy-2,2′-bipyridine-N,N′-dioxide compounds, especially 3,3′,4,4′-tetrahydroxy-2,2′-bipyridine-N,N′-dioxide (Orellanine), using particular administration protocols and dosing regimens, as well as pharmaceutical compositions suitable for use in the treatment methods that are provided.
REFERENCES:
patent: 6403373 (2002-06-01), Scanlan et al.
patent: 6440663 (2002-08-01), Scanlan et al.
patent: 2005/0261178 (2005-11-01), Warnaar et al.
patent: 2006/0134708 (2006-06-01), Yang
patent: 1359941 (2002-07-01), None
patent: 0 160 250 (1985-06-01), None
patent: 1 712 234 (2006-10-01), None
patent: 2001288110 (2001-10-01), None
patent: 2188026 (2002-08-01), None
patent: WO 2004/075887 (2004-09-01), None
patent: WO 2007/044015 (2007-04-01), None
patent: WO 2007/059082 (2007-05-01), None
Rapior et al ‘Intoxication byCortinarius orellanus: Detection and assay of orellanine in biological fluids and renal biopsies’ Mycopathologia, vol. 108, p. 155-161, 1989.
Atkins, MB et al., 2007, Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference, Clin. Cancer Res. 13:667-670.
Garcia, JA et al., 2007, Recent progress in the management of advanced renal cell carcinoma, CA Cancer J. Clin. 57: 112-25.
Sutphin, PD et al., 2007, Targeting the loss of the von Hippel-Lindau Tumor Suppressor Gene in Renal Carcinoma Cells, Cancer Res. 67: 5896-5905.
Buvall Lisa
Haraldsson Börje
Nilsson Ulf
Nyström Jenny
Barber Lynn E.
Fetterolf Brandon
Stone Christopher R
LandOfFree
Treatment of renal cell carcinoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of renal cell carcinoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of renal cell carcinoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4305616